BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26150445)

  • 1. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.
    Murphy CC; Harlan LC; Warren JL; Geiger AM
    J Clin Oncol; 2015 Aug; 33(23):2530-6. PubMed ID: 26150445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Explaining black-white differences in receipt of recommended colon cancer treatment.
    Baldwin LM; Dobie SA; Billingsley K; Cai Y; Wright GE; Dominitz JA; Barlow W; Warren JL; Taplin SH
    J Natl Cancer Inst; 2005 Aug; 97(16):1211-20. PubMed ID: 16106026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.
    Davidoff AJ; Rapp T; Onukwugha E; Zuckerman IH; Hanna N; Pandya N; Mullins CD
    Med Care; 2009 Dec; 47(12):1229-36. PubMed ID: 19786906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States.
    Hao S; Snyder RA; Irish W; Parikh AA
    PLoS Med; 2021 Oct; 18(10):e1003842. PubMed ID: 34695123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
    Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA
    Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual treatment disparities after oncology referral for rectal cancer.
    Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
    J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of black/white differences in colon cancer survival.
    Mayberry RM; Coates RJ; Hill HA; Click LA; Chen VW; Austin DF; Redmond CK; Fenoglio-Preiser CM; Hunter CP; Haynes MA
    J Natl Cancer Inst; 1995 Nov; 87(22):1686-93. PubMed ID: 7473817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
    Lai Y; Wang C; Civan JM; Palazzo JP; Ye Z; Hyslop T; Lin J; Myers RE; Li B; Jiang B; Sama A; Xing J; Yang H
    Gastroenterology; 2016 May; 150(5):1135-1146. PubMed ID: 26836586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer.
    Simpson DR; Martínez ME; Gupta S; Hattangadi-Gluth J; Mell LK; Heestand G; Fanta P; Ramamoorthy S; Le QT; Murphy JD
    J Natl Cancer Inst; 2013 Dec; 105(23):1814-20. PubMed ID: 24231453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
    Griggs JJ; Hawley ST; Graff JJ; Hamilton AS; Jagsi R; Janz NK; Mujahid MS; Friese CR; Salem B; Abrahamse PH; Katz SJ
    J Clin Oncol; 2012 Sep; 30(25):3058-64. PubMed ID: 22869890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment at Academic Centers Decreases Insurance-Based Survival Disparities in Colon Cancer.
    Cabo J; Shu X; Shu XO; Parikh A; Bailey C
    J Surg Res; 2020 Jan; 245():265-272. PubMed ID: 31421372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insurance status as a modifier of the association between race and stage of prostate cancer diagnosis in Florida during 1995 and 2013.
    Ramirez E; Morano J; Beguiristain T; Castro G; de la Vega PR; Nieder AM; Barengo NC
    Cancer Epidemiol; 2019 Apr; 59():104-108. PubMed ID: 30731402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
    Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
    Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
    Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
    J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of health insurance and race with treatment and survival in patients with metastatic colorectal cancer.
    Mitsakos AT; Irish W; Parikh AA; Snyder RA
    PLoS One; 2022; 17(2):e0263818. PubMed ID: 35176030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.